Optimizing use of quinolones in the critically ill

Seminars in Respiratory and Critical Care Medicine

Volumn 28, Issue 6, 2007, Pages 586-595

  Yang, Jenny C ^a   Tsuji, Brian T ^a   Forrest, Alan ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Critically ill; Fluoroquinolones; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE INHIBITOR; DNA TOPOISOMERASE IV; GATIFLOXACIN; GYRASE INHIBITOR; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ABDOMINAL PAIN; ABNORMAL VISION; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ANAPHYLAXIS; ANOREXIA; AREA UNDER THE CURVE; ARTHROPATHY; BACTERIAL INFECTION; BLISTER; BURN; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; CRYSTALLURIA; DELIRIUM; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; EXTRACELLULAR FLUID; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; HEADACHE; HEMATURIA; HEMOLYTIC ANEMIA; HEPATITIS; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; IMMUNOPATHOLOGY; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FUNCTION; LEUKOPENIA; LIVER DISEASE; LIVER FAILURE; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MUSCULOSKELETAL DISEASE; NAUSEA; OBSTRUCTIVE JAUNDICE; PHARMACODYNAMICS; PHOTOSENSITIVITY; PIGMENT DISORDER; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SIDE EFFECT; SKIN BLEEDING; SKIN DISEASE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TASTE DISORDER; TENDINITIS; TENDON RUPTURE; THROMBOCYTOPENIA; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; TREMOR; UREMIA; URTICARIA; VOMITING;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 37649000389     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996405     Document Type: Review

References (79)

1. Vincent J-L, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 1995;274:639-644
2. Highet VS, Forrest A, Ballow CH, et al. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother 1999;43(Suppl A):55-63
3. Zhou J, Dong Y, Zhao X, et al. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 2000;182:517-525
4. Talbot GH, Bradley J, Edwards JE Jr, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. [see comment] [erratum appears in Clin Infect Dis 2006;42:1065] Clin Infect Dis 2006;42:657-668
5. Robicsek A, Jacoby GA, Hooper DC, et al. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006;6:629-640
6. Jacoby GA, Walsh KE, Mills DM, et al. qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother 2006;50:1178-1182
7. Truong-Bolduc QC, Strahilevitz J, Hooper DC, et al. A new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:1104-1107
8. Ince D, Zhang X, Silver LC, et al. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother 2002;46:3370-3380
9. Gore J, Bryant Z, Stone MD, et al. Mechanochemical analysis of DNA gyrase using rotor bead tracking. Nature 2006;439:100-104
10. Champoux JJ, Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413
11. Wang JC, Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-440
12. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement. Vol 27. Wayne, PA: Clinical and Laboratory Standards Institute; 2007
13. Jones RN, Beach ML, Pfaller MA, et al. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! Diagn Microbiol Infect Dis 2001;41:161-163
14. Jones RN, Pfaller MA, Jones RN, Pfaller MA. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Clin Infect Dis 2000;31(Suppl 2):S16-S23
15. 14a. Yang JC, Bulitta JB, Forrest AF, Tsuji BT. High inocula Pseudomonas aeruginosa attenuates colistin bactericidal activity and alters pharmacodynamics. Paper presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 16-20, 2007; Chicago, IL
16. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38(Suppl 4):S341-S345
17. Campillo B, Dupeyron C, Richardet JP, et al. Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect 2001;127:443-450
18. Dziekan G, Hahn A, Thune K, et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J Hosp Infect 2000;46:263-270
19. Graffunder EM, Venezia RA, Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002;49:999-1005
20. Weber SG, Gold HS, Hooper DC, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415-1422
21. Lautenbach E, Strom BL, Bilker WB, et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001;33: 1288-1294
22. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473-478
23. Ziha-Zarifi I, Llanes C, Kohler T, et al. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999;43:287-291
24. Le Thomas I, Couetdic G, Clermont O, et al. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. [see comment] J Antimicrob Chemother 2001;48:553-555
25. Drlica K, Zhao X, Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997;61:377-392
26. Schmitz FJ, Hofmann B, Hansen B, et al. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998;41:481-484
27. Drlica K, Zhao X, Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007;44:681-688
28. Barnard FM, Maxwell A, Barnard FM, Maxwell A. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). Antimicrob Agents Chemother 2001;45:1994-2000
29. Bast DJ, Low DE, Duncan CL, et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother 2000;44:3049-3054
30. Jorgensen JH, Weigel LM, Ferraro MJ, et al. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother 1999;43:329-334
31. Janoir C, Zeller V, Kitzis MD, et al. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996;40:2760-2764
32. Martinez-Martinez L, Pascual A, Jacoby GA, et al. Quinolone resistance from a transferable plasmid. Lancet 1998;351:797-799
33. Tran JH, Jacoby GA, Hooper DC, et al. Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother 2005;49:3050-3052
34. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-527
35. Hansen GT, Zhao X, Drlica K, et al. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents 2006;27:120-124
36. Schentag JJ, Nix DE, Adelman MH, et al. Mathematical examination of dual individualization principles, I: Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP 1991;25:1050-1057
37. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-1081
38. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. [see comment] JAMA 1998;279:125-129
39. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793-2797
40. Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004;189:1590-1597
41. Drusano GL, Weir M, Forrest A, et al. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother 1987;31:860-864
42. Gonzalez MA, Moranchel AH, Duran S, et al. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother 1985;28:235-239
43. Overholser BR, Kays MB, Lagvankar S, et al. Pharmacokinetics of intravenously administered levofloxacin in men and women. Pharmacotherapy 2005;25:1310-1318
44. Chow AT, Fowler C, Williams RR, et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 2001;45:2122-2125
45. Stass H, Kubitza D, Halabi A, et al. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002;53:232-237
46. Ostergaard C, Sorensen TK, Knudsen JD, et al. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob Agents Chemother 1998;42:1706-1712
47. Stass H, Kubitza D, Moller JG, et al. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Br J Clin Pharmacol 2005;59:536-541
48. Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 2000;20(6 Pt 2):49S-58S
49. Olsen KM, Rebuck JA, Weidenbach T, et al. Pharmacokinetics of intravenous trovafloxacin in critically ill adults. Pharmacotherapy 2000;20:400-404
50. Noreddin AM, H VL, Zhanel GG. Pharmacokinetics and pharmacodynamics of the new quinolones. Curr Opin Pharmacol 2001;1:459-463
51. Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999;44:835-838
52. Birmingham MC, Guarino R, Heller A, et al. Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose. J Antimicrob Chemother 1999;43(Suppl A):43-48
53. Drusano GL, Plaisance KI, Forrest A, et al. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother 1986;30:440-443
54. Capitano B, Mattoes HM, Shore E, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 2004;125:965-973
55. Rodvold KA, Danziger LH, Gotfried MH, et al. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003;47:2450-2457
56. Bellmann R, Egger P, Gritsch W, et al. Elimination of levofloxacin in critically ill patients with renal failure: influence of continuous veno-venous hemofiltration. Int J Clin Pharmacol Ther 2002;40:142-149
57. Jones EM, McMullin CM, Hedges AJ, et al. The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother 1997;40:121-124
58. Fuhrmann V, Schenk P, Jaeger W, et al. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother 2004;54:780-784
59. Malone RS, Fish DN, Abraham E, et al. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001;45:2949-2954
60. Vance-Bryan K, Guay DR, Rotschafer JC, et al. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990;19:434-461
61. Aminimanizani A, Beringer P, Jelliffe R, et al. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001;40:169-187
62. Gous A, Lipman J, Scribante J, et al. Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. Int J Antimicrob Agents 2005;26:50-55
63. Garrelts JC, Jost G, Kowalsky SF, et al. Ciprofloxacin pharmacokinetics in burn patients. Antimicrob Agents Chemother 1996;40:1153-1156
64. Kiser TH, Hoody DW, Obritsch MD, et al. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrob Agents Chemother 2006;50:1937-1945
65. Lesne-Hulin A, Bourget P, Ravat F, et al. Clinical pharmacokinetics of ciprofloxacin in patients with major burns. Eur J Clin Pharmacol 1999;55:515-519
66. Ambrose PG, Bhavnani SM, Owens RC Jr, et al. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003;17:529-543
67. Forrest A, Chodosh S, Amantea MA, et al. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997;40(Suppl A):45-57
68. Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483-490
69. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112:275-285
70. Craig WA, Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10 quiz 11-2
71. Firsov AA, Zinner SH, Vostrov SN, et al. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother 2002;50:533-539
72. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, et al. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996;40:627-632
73. Owens RC Jr, Ambrose PG, Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41(Suppl 2):S144-S157
74. Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004;26:940-950
75. Lipsky BA, Baker CA, Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999;28:352-364
76. Lipman J, Allworth A, Wallis SC, et al. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 2000;31:1131-1133
77. Akahane K, Sekiguchi M, Une T, et al. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1989;33:1704-1708
78. Quigley CA, Lederman JR, Quigley CA, Lederman JR. Possible gatifloxacin-induced seizure. Ann Pharmacother 2004;38:235-237
79. Owens RC Jr, Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004;64:1091-1124